Search Results - "Triplitt, Curtis"

Assessment of pancreatic β-cell function: review of methods and clinical applications by Cersosimo, Eugenio, Solis-Herrera, Carolina, Trautmann, Michael E, Malloy, Jaret, Triplitt, Curtis L

“…Type 2 diabetes mellitus (T2DM) is characterized by a progressive failure of pancreatic β-cell function (BCF) with insulin resistance. Once insulin…”
Get more information

Therapeutic Manipulation of Myocardial Metabolism by Honka, Henri, Solis-Herrera, Carolina, Triplitt, Curtis, Norton, Luke, Butler, Javed, DeFronzo, Ralph A.

“…The mechanisms responsible for the positive and unexpected cardiovascular effects of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1…”
Get full text

Understanding the kidneys' role in blood glucose regulation by Triplitt, Curtis L

“…While not traditionally discussed, the kidneys' contributions to maintaining glucose homeostasis are significant and include such functions as release of…”
Get full text

887-P: Renal Benefit of Dapagliflozin Therapy in Hyperfiltering Type 2 Diabetes Patients by BASKOY, GOZDE, QIN, YUEJUAN, CERSOSIMO, EUGENIO, SOLIS-HERRERA, CAROLINA, ADAMS, JOHN M., DEFRONZO, RALPH A., TRIPLITT, CURTIS L.

“…Aim: To investigate the benefits of dapagliflozin [DAPA] on renal hemodynamics in type 2 diabetes patients [T2D] with glomerular hyperfiltration. Design and…”
Get full text

124-OR: Effects of Dapagliflozin Therapy on Renal Hemodynamics in Type 2 Diabetes Patients by QIN, YUEJUAN, BASKOY, GOZDE, TRIPLITT, CURTIS L., SOLIS-HERRERA, CAROLINA, ADAMS__III, JOHN M., DEFRONZO, RALPH A., CERSOSIMO, EUGENIO

“…Aim: To investigate the renal hemodynamic effects of SGLT-2i therapy in patients with type 2 diabetes [T2D]. Design & Methods: We recruited 24 drug naïve T2D,…”
Get full text

Examining the mechanisms of glucose regulation by Triplitt, Curtis L

“…The prevalence of diabetes mellitus (DM) increased by 49% between 1990 and 2000, reaching nearly epidemic proportions. In 2010, DM (type 1 or 2) was estimated…”
Get full text

Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists by Kane, Michael P, Triplitt, Curtis L, Solis-Herrera, Carolina D

“…Abstract Purpose To provide pharmacists with information on counseling patients with type 2 diabetes (T2D) receiving oral semaglutide. Summary Oral…”
Get full text

A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement by Riddle, Matthew C., D’Alessio, David A., Brunton, Stephen A., Triplitt, Curtis L.

Get full text

A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement by Riddle, Matthew C., D’Alessio, David A., Brunton, Stephen A., Triplitt, Curtis L.

Get full text

857-P: Mechanisms of Dapagliflozin to Reduce Intraglomerular Pressure in Patients with Type 2 Diabetes by BARKHORDARIAN, MARYAM, TRIPLITT, CURTIS L., SOLIS-HERRERA, CAROLINA, ADAMS, JOHN M., DEFRONZO, RALPH A., CERSOSIMO, EUGENIO

“…Aim: To examine the renal hemodynamic effects of SGLT-2i therapy in type 2 diabetes patients [T2D]. Design & Methods: T2D (n=20) with normal GFR measured with…”
Get full text

Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients by Al Jobori, Hussein, Daniele, Giuseppe, Adams, John, Cersosimo, Eugenio, Triplitt, Curtis, DeFronzo, Ralph A., Abdul‐Ghani, Muhammad

“…Aim To examine metabolic factors that influence ketone production after sodium‐glucose cotransport inhibitor (SGLT2) administration. Research design and…”
Get full text

99-LB: Myocardial Blood Flow in Association with Baseline Ejection Fraction after Elevation in Plasma Ketones in Patients with T2DM and Heart Failure by SOLIS-HERRERA, CAROLINA, QIN, YUEJUAN, HONKA, HENRI, ACOSTA, FRANCISCA M., MOODY, ALEXANDER, CHAVEZ, ALBERTO, TRIPLITT, CURTIS L., CLARKE, GEOFFREY D., CERSOSIMO, EUGENIO, DEFRONZO, RALPH A.

“…Background: SGLT2 inhibitors have been shown to provide CV benefits in HFpEF and HFrEF patients with and without diabetes. The underlying mechanisms continue…”
Get full text

Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy by Martinez, Robert, Al-Jobori, Hussein, Ali, Ali M, Adams, John, Abdul-Ghani, Muhammad, Triplitt, Curtis, DeFronzo, Ralph A, Cersosimo, Eugenio

“…The decrement in plasma glucose concentration with SGLT2 inhibitors (SGLT2i) is blunted by a rise in endogenous glucose production (EGP). We investigated the…”
Get full text

Addressing Hypoglycemia Risk During Care Transitions by Clements, Jennifer N., Neumiller, Joshua J., Triplitt, Curtis

“…Insulin use is a major risk factor for developing hypoglycemia (Table 1). In 2022, Myers et al indicated 6.8% of people with type 1 diabetes (T1D) and 3.7% of…”
Get full text

Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors by Alatrach, Mariam, Laichuthai, Nitchakarn, Martinez, Robert, Agyin, Christina, Ali, Ali Muhammed, Al-Jobori, Hussein, Lavynenko, Olga, Adams, John, Triplitt, Curtis, DeFronzo, Ralph, Cersosimo, Eugenio, Abdul-Ghani, Muhammad

“…Sodium-glucose cotransport 2 inhibitors (SGLT2i) lower plasma glucose but stimulate endogenous glucose production (EGP). The current study examined the effect…”
Get full text

Oh, What Times We Live In by Triplitt, Curtis L

Get full text

644-P: Effect of PharmacologIC (EPIC) Therapy on Insulin Sensitivity and Beta-Cell Function in Prediabetes (PreDM) by VELAZQUEZ, ALBERTO O. CHAVEZ, ALI, EMAD, MEROVCI, AURORA, AGYIN, CHRISTINA, TERASAWA, TOMOKO, ABDUL-GHANI, MUHAMMAD, TRIPLITT, CURTIS L., CERSOSIMO, EUGENIO, DEFRONZO, RALPH A.

“…Treating PreDM with medications that target specific pathophysiologic defects can slow/prevent the progression to type 2 diabetes mellitus (T2DM) . While the…”
Get full text

175-OR: Effect of Hyperketonemia on Cardiac Efficiency in Patients with Heart Failure and Type 2 Diabetes by SOLIS-HERRERA, CAROLINA, QIN, YUEJUAN, HONKA, HENRI, MOODY, ALEXANDER, CLARKE, GEOFFREY D., TRIPLITT, CURTIS L., CERSOSIMO, EUGENIO, DEFRONZO, RALPH A.

“…Mechanism (s) responsible for the cardiac benefits of SGLT2 inhibitors remain unknown. Aim: To examine the effect of increased ketone concentration (with…”
Get full text

68-LB: Early Pharmacological Intervention (EPIC) to Preserve Beta-Cell Function in Prediabetes (PreDM) by CHAVEZ, ALBERTO, MEROVCI, AURORA, NEPPALA, SIVARAM, CRUZ MORENO, LUIS A., BASKOY, GOZDE, ACOSTA, FRANCISCA M., HANSIS-DIARTE, ANDREA A., PUCKETT, CURTISS L., ADAMS, JOHN M., ABDUL-GHANI, MUHAMMAD, TRIPLITT, CURTIS L., CERSOSIMO, EUGENIO, DEFRONZO, RALPH A.

“…Beta cell failure is the key pathophysiologic determinant in progression from PreDM to type 2 diabetes (T2D). Lifestyle modifications frequently are…”
Get full text

97-LB: Empagliflozin Improves Cardiopulmonary Function and VE/VCO2 in Patients with T2D and HFrEF by QIN, YUEJUAN, ACOSTA, FRANCISCA M., NEPPALA, SIVARAM, CORTES, TIFFANY M., STEPANENKO, ALLISON, MOODY, ALEXANDER, SANCHEZ, NOAH D., BROWN, MARISSA, CRUZ MORENO, LUIS A., TRIPLITT, CURTIS L., CLARKE, GEOFFREY D., CERSOSIMO, EUGENIO, ESPINOZA, SARA E., DEFRONZO, RALPH A., SOLIS-HERRERA, CAROLINA

“…Background: Cardioprotective benefits of SGLT2 inhibitors (SGLT2i) are well established. However, their effects on cardiopulmonary function measured by CPET in…”
Get full text